Board of Directors
George B. Abercrombie, Chairman of the Board
Mr. Abercrombie was appointed to the Board in October 2011 and appointed Chairman May 2013. He has over 30 years of experience as a business leader in the pharmaceutical industry, and most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. He began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Currently, Mr. Abercrombie serves as a member of the Board of Directors of Tranzyme Pharma and as Chairman of the Board of Brickell Biotech. Additionally, he is a member of the Board of Directors of Project HOPE and a Senior Scholar at Duke University’s Fuqua School of Business.
Fred E. Cohen, M.D., D.Phil
Dr. Fred E. Cohen, was appointed to the Board in July 2013. Dr. Cohen is a partner at TPG, a private equity firm he joined in 2001, and serves as a Partner and Managing Director at TPG Biotech. Dr. Cohen has been a member of the faculty of University of California, San Francisco (UCSF) since 1986. At UCSF, Dr. Cohen has served as an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford, and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. Dr. Cohen was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. Currently Dr. Cohen serves on the Board of Directors of CareDx, Inc., Five Prime Therapeutics, Inc., Genomic Health, Tandem Diabetes Care, Inc., and the Boards of several privately held companies.
Stanley C. Erck
Stanley C. Erck was elected a Director in December 2008. Mr. Erck was named President and Chief Executive Officer of Novavax in April 2011. From 2000-2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidates. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of Novavax, MaxCyte, and the MdBio Foundation, a private charitable organization. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Nancy Hutson, Ph.D.
Dr. Hutson was appointed to the Board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc. in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as Director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Currently, Dr. Hutson currently serves on the board of directors for Cubist Pharmaceuticals, Inc. and Endo Pharmaceuticals Holdings, Inc., and is an active member on the board of directors for Planned Parenthood of Connecticut. She is also involved in several professional societies, including but not limited to, the American Association for the Advancement of Science and the American Physiological Society. Dr. Hutson received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University.
Robert A. Ingram
Mr. Ingram was appointed to the Board in August 2015. Bob Ingram joined Hatteras Venture Partners as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline (GSK) and served as Vice Chairman Pharmaceuticals of GSK until January 1, 2010.
Bob serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc., and is Chairman of Viamet, a private company focused on anti-infective research. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. Bob graduated from Eastern Illinois University with a B.S. degree in Business Administration.
In addition to his professional responsibilities, Bob formed and chaired the CEO Roundtable on Cancer at the request of former President George H.W. Bush, and he is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In November 2014, Bob received the North Carolina Award, the highest civilian honor the state can bestow on an individual. He received the award for public service.
Bob is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of the Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.
Kenneth B. Lee, Jr.
Kenneth B. Lee, Jr. was appointed to the Board in June 2011. Mr. Lee has over 35 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is currently a general partner for Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young, where he was most recently Managing Director of the firm's health sciences corporate finance group. Mr. Lee was also Chairman of the Ernst & Young Life Sciences Practice and Co-Chairman of Ernst & Young’s International Life Science Parctice. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently an active member on the board of directors of biotech companies Maxygen and Pozen, Inc., as well as the NC Biosciences Organization (NCBIO). Previously, Mr. Lee served on the boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, OSI Pharmaceuticals and A.M. Pappas & Associates.
Sanj K. Patel
Sanj K. Patel is the Chairman and CEO of Kiniksa Pharmaceuticals, which was formed in June 2015 to develop therapies for patients with devastating diseases and unmet medical needs. He brings more than 25 years of experience in the pharmaceutical and biotech industries and has a combination of scientific, clinical and commercial skills. Sanj K. Patel created Synageva in June 2008 to focus on rare diseases, and designed and initiated its lead program (Kanuma®) for LAL Deficiency in July 2008. He took the company public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in five years. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.3B (including cash), which represented the highest premium ever paid for a biotech company valued over $5B.
Prior to Synageva, he was at Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics franchise and led the U.S. launch of Myozyme®, in addition to sales and marketing responsibility for Cerezyme®, Fabrazyme® and Aldurazyme®. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council for all Genzyme divisions, including Therapeutics, Oncology and Transplant. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization of several treatments. Notably, Sanj led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, Sanj held roles in clinical research and commercial operations with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa/Otsuka Pharmaceuticals. Sanj obtained his BSc with Honors in Pure and Applied Biology (Biotechnology) from the University of the South Bank, London. He completed his management and business studies at Ealing College, London and his Pharmacology research program at the Wellcome Foundation and King's College. Sanj is also a member of the Board of Directors for Syros Pharmaceuticals.
Jon P. Stonehouse
Jon P. Stonehouse was elected BioCryst Pharmaceuticals, Inc.’s President and Chief Executive Officer in January 2007. Having been a pharmaceutical executive for more than 20 years, Mr. Stonehouse has strong commercialization, financial transaction, business development, and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.